A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas
Reason given: Change in corporate strategy
Key facts
- Where
- Ann Arbor, Aurora, Austin, Baltimore, Bethesda, Billings, Dallas, Fort Wayne, Fort Worth, Greenville, Houston, Jacksonville, Los Angeles, Monterey, Morristown, New York, Norfolk, Orlando, Redondo Beach, Rochester, Rock Hill, San Antonio, San Diego, Santa Barbara, Santa Rosa, Tyler, Vancouver, and Worcester, United StatesSee the 30 sites
- Phase
- Phase 1
Where in United States
- University of MichiganAnn Arbor, United StatesNo longer taking part
- Rocky Mountain Cancer CentersAurora, United StatesNo longer taking part
- Texas Oncology-Austin MidtownAustin, United StatesNo longer taking part
- University of Maryland Greenebaum Comprehensive Cancer CenterBaltimore, United StatesNo longer taking part
- The Center for Cancer and Blood Disorders a division of American Oncology Partners of Maryland, PABethesda, United StatesNo longer taking part
- SCL Health, St. Vincent Frontier Cancer CenterBillings, United StatesNo longer taking part
- Texas Oncology - Baylor Charles A. Sammons Cancer CenterDallas, United StatesNo longer taking part
- Fort Wayne Medical Oncology and HematologyFort Wayne, United StatesNo longer taking part
- Texas Oncology - Fort Worth Cancer CenterFort Worth, United StatesNo longer taking part
- PRISMA Health/ITORGreenville, United StatesNo longer taking part
- University of Texas M.D. Anderson Cancer CenterHouston, United StatesNo longer taking part
- Mayo Clinic- JacksonvilleJacksonville, United StatesNo longer taking part
- University of California, Los AngelesLos Angeles, United StatesNo longer taking part
- Pacific Cancer CareMonterey, United StatesNo longer taking part
- Morristown Medical CenterMorristown, United StatesNo longer taking part
- Manhattan Hematology OncologyNew York, United StatesNo longer taking part
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesNo longer taking part
- Virginia Oncology AssociatesNorfolk, United StatesNo longer taking part
- Orlando HealthOrlando, United StatesNo longer taking part
- Torrance Memorial Physician NetworkRedondo Beach, United StatesNo longer taking part
- Mayo Clinic - RochesterRochester, United StatesNo longer taking part
- Carolina Blood and Cancer Care AssociatesRock Hill, United StatesNo longer taking part
- University of Texas Health Science Center at San Antonio, Mays Cancer CenterSan Antonio, United StatesNo longer taking part
- Sharp Clinical Oncology ResearchSan Diego, United StatesNo longer taking part
- UCSD Moores Cancer CenterSan Diego, United StatesNo longer taking part
- Ridley-Tree Cancer CenterSanta Barbara, United StatesNo longer taking part
- St. Joseph Heritage HeathcareSanta Rosa, United StatesNo longer taking part
- Texas Oncology - TylerTyler, United StatesNo longer taking part
- Northwest Cancer Specialists, P.C. - Compass OncologyVancouver, United StatesNo longer taking part
- Umass Memorial Medical CenterWorcester, United StatesNo longer taking part
Trial details
- Who runs it
- Aptose Biosciences Inc.
- Trial code
- NCT03893682
- Record updated
- 7 March 2025
- Original description
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to two or more lines of established therapy or for whom no other treatment options are available.Read full original descriptionShow less
A Phase Ia/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients With CLL/SLL or Non-Hodgkin's Lymphomas
This study is being done to evaluate the safety, tolerability and effectiveness of Oral CG-806 for the treatment of patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or Non-Hodgkin's Lymphomas who have failed or are intolerant to two or more lines of established therapy or for whom no other treatment options are available.
Inclusion: Age ≥ 18 years; Life expectancy of at least 2 months; ECOG Performance Status ≤ 2; Patients must be able to swallow capsules; Adequate hematologic parameters, unless cytopenias are disease caused; Adequate renal, liver and cardiac function parameters.
Exclusion: Patients with GVHD requiring systemic immunosuppressive therapy; Treatment with other investigational drugs within 14 days prior to first study treatment administration; Uncontrolled leptomeningeal disease, auto-immune hemolytic anemia and uncontrolled and clinical significant disease related metabolic disorder; Clinically significant intravascular coagulation.